| 000 | 01856 a2200541 4500 | ||
|---|---|---|---|
| 005 | 20250516052624.0 | ||
| 264 | 0 | _c20120314 | |
| 008 | 201203s 0 0 eng d | ||
| 022 | _a1432-0851 | ||
| 024 | 7 |
_a10.1007/s00262-011-1093-4 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aVetsika, Eleni-Kyriaki | |
| 245 | 0 | 0 |
_aImmunological responses in cancer patients after vaccination with the therapeutic telomerase-specific vaccine Vx-001. _h[electronic resource] |
| 260 |
_bCancer immunology, immunotherapy : CII _cFeb 2012 |
||
| 300 |
_a157-168 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aCD8-Positive T-Lymphocytes _ximmunology |
| 650 | 0 | 4 | _aCancer Vaccines |
| 650 | 0 | 4 |
_aCarcinoma, Non-Small-Cell Lung _xdrug therapy |
| 650 | 0 | 4 | _aCytotoxicity, Immunologic |
| 650 | 0 | 4 | _aEnzyme-Linked Immunospot Assay |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aHLA-A2 Antigen _ximmunology |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aImmunotherapy |
| 650 | 0 | 4 |
_aInterferon-gamma _xmetabolism |
| 650 | 0 | 4 |
_aLung Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aNeoplasm Staging |
| 650 | 0 | 4 | _aSurvival Analysis |
| 650 | 0 | 4 | _aTelomerase |
| 650 | 0 | 4 | _aVaccination |
| 700 | 1 | _aKonsolakis, Georgios | |
| 700 | 1 | _aAggouraki, Despoina | |
| 700 | 1 | _aKotsakis, Athanasios | |
| 700 | 1 | _aPapadimitraki, Elisavet | |
| 700 | 1 | _aChristou, Soultana | |
| 700 | 1 | _aMenez-Jamet, Jeanne | |
| 700 | 1 | _aKosmatopoulos, Kostas | |
| 700 | 1 | _aGeorgoulias, Vassilis | |
| 700 | 1 | _aMavroudis, Dimitris | |
| 773 | 0 |
_tCancer immunology, immunotherapy : CII _gvol. 61 _gno. 2 _gp. 157-168 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s00262-011-1093-4 _zAvailable from publisher's website |
| 999 |
_c21101662 _d21101662 |
||